HOME >> BIOLOGY >> NEWS
New strategies against disease revealed as scientists probe genes' tasks

DENVER, CO - A combination of genomics and computing technologies has produced exciting new leads for improving human health and understanding the basic processes of life, scientists said today at the American Association for the Advancement of Science (AAAS) Annual Meeting.

Those three million or so letters in the human genome sequence may have seemed like a lot of information to handle. But, consider the trillions of cells in the human body, each with thousands of genes working together-in combinations changing from one cell type to another and from one moment to the next.

"If the goal of the human genome project was to define genes, an important goal of the next phase is to determine how these genes, and the proteins they encode, are connected together in large regulatory and signaling circuits inside the cell," said Trey Ideker of the Whitehead Institute. "If you think of electronics, it's like we know where the transistors are, but not how they're wired up."

Scientists are sorting all this out using gene labs on chips approximately the size of a postage-stamp, called "DNA microarrays," that can provide a profile of all the genes being expressed in a given cell. The results are helping to shed light on health conditions from infectious disease to brain disorders, scientists reported during a series of seminars on "Microarrays and Functional Genomics" at the AAAS Annual Meeting.

To understand how microarray chips work, think of the DNA double helix as a zipper that can be unzipped down the middle, splitting the molecule into two single strands. A microarray chip is covered with "unzipped" DNA sequences representing thousands of genes. To see whether a sample of genetic material contains any of those genes, researchers first process the sample to "unzip" its active genes and tag them with a fluorescent marker.

When this material is washed over the microarray chip, the single strands of DNA zip themselves up with their com
'"/>


16-Feb-2003


Page: 1 2 3

Related biology news :

1. Survival strategies in nature
2. Sophisticated silencing strategies
3. Largest brain repair initiative in MS will speed strategies to restore nerve function
4. Advance in developing biological strategies to produce hydrogen and sequester carbon dioxide
5. Host response to anthrax lethal toxin suggests some current treatment strategies are inappropriate
6. Plant pathologists to discuss strategies for global crop protection at the APS Annual Meeting
7. Radiation-resistant organism reveals its defense strategies
8. Professor develops strategies to control exotic plant species
9. Los Alamos researchers recommend AIDS vaccine strategies
10. Conference focuses on practical strategies for preventing and treating obesity
11. Chemgenex reports use of chemical genomics strategies to advance drug development

Post Your Comments:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: